News

Date Title
February 14, 2018
SeraCare Life Sciences is expanding what is already the most comprehensive suite of clinical genomics development, validation, and QC tools with the launch of the SeraseqTM Breast CNV and Seraseq Lung and Brain CNV Mix. Reference materials that analyze for CNVs allow for a complete and comprehensive variant assessment of DNA-based tumor profiling and diagnostic molecular assays beyond SNVs and indels. These expert-designed products are built with innovative biosynthetic technology that is easily scalable to incorporate new CNVs over time.
December 8, 2017
The decision matrix for liquid biopsies is defined by the sample, method, the analysis platform, and the desired output. For typical platforms -- molecular assays like PCR or NGS -- sample acquisition and preparation is critical, as analytes often exist at extremely low concentrations within the sample, with seemingly overwhelming quantities of interferences.
October 12, 2017
NEW YORK (GenomeWeb) – Stakeholders in the liquid biopsy field gathered yesterday to discuss the state of the science for blood-based cancer genomics, to quantify the challenges facing test developers and regulators, and to discuss ongoing projects and new data.
August 22, 2017
To ensure the accuracy of patient testing results, clinical next-generation sequencing (NGS) labs must track metrics across their assay’s workflow to determine whether runs were within established limits. Without software to help manage this data, labs must manually compile and trend data to determine whether a run passed or failed, introducing the possibility of transcription errors and adding to the turnaround time for patient results.
August 1, 2017
SeraCare Life Sciences, Milford, Mass, has launched Seraseq Circulating Tumor DNA v2 reference materials, aimed to closely mimic the performance attributes of ctDNA derived from clinical specimens.
July 24, 2017
NEW YORK (GenomeWeb) – As liquid biopsy genetic tests have rocketed into clinical practice over the last handful of years, clinical researchers, test developers, and others have begun to pay increasing attention to a relative lack of tools to ensure assays are validated and performed according to common, or at least equivalent standards
July 18, 2017
The lack of adequate circulating tumour DNA reference materials for developing and measuring safe, accurate, and reproducible assays continues to be a challenge for clinical labs.
June 28, 2017
Clinical labs are adopting next-generation sequencing technology at ever increasing rates. As sequencing costs decrease and the clinical utility of many applications increase, labs are rushing to implement clinical sequencing assays in part to keep critical patient testing volumes for cancer and inherited disease testing from leaving their networks.